Esperion Therapeutics (ESPR) Gross Profit Growth (1y) (2020 - 2026)
Esperion Therapeutics (ESPR) Gross Profit Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 5.06% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.59% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -18.38% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -7.66% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -0.34% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 42.12% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 14.77% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 36.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.09% |
| Sep 30, 2025 | 33.99% |
| Jun 30, 2025 | -7.53% |
| Mar 31, 2025 | -73.79% |
| Dec 31, 2024 | 109.07% |
| Sep 30, 2024 | 66.79% |
| Jun 30, 2024 | 206.45% |
| Mar 31, 2024 | 907.02% |
| Dec 31, 2023 | 41.89% |
| Sep 30, 2023 | 65.08% |
| Jun 30, 2023 | 96.59% |
| Mar 31, 2023 | 8.25% |
| Dec 31, 2022 | 41.95% |
| Sep 30, 2022 | 40.93% |
| Jun 30, 2022 | -75.13% |
| Mar 31, 2022 | 89.07% |
| Dec 31, 2021 | 29.89% |
| Sep 30, 2021 | 148.76% |
| Jun 30, 2021 | -81.66% |
| Mar 31, 2021 | 242.40% |